Cancer Genetics, Inc (CGIX): John Pappajohn , director 10% owner of Cancer Genetics, Inc purchased 5,000 shares on Aug 26, 2015. The Insider buying transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $9.61 per share for a total value of $48,060.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 18, 2016, Howard Mcleod (director) purchased 1,000 shares at $2.71 per share price.On Mar 17, 2016, Michael J. Welsh (director) purchased 40 shares at $2.42 per share price.Also, On Mar 17, 2016, Panna Sharma (CEO) purchased 1,500 shares at $2.59 per share price.On Mar 17, 2016, John Pappajohn (director 10% owner) purchased 50,000 shares at $2.64 per share price.
Cancer Genetics Inc (CGIX) witnessed a volatile trading activity on Wednesday May 25, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $2.14 and reached the intraday high at $2.21. The bulls started the profit booking and pushed the shares to intraday low of $2.1324. The trading session was marked by a volume range of 91,481 shares exchanging hands. The 52-week high of the shares is $12.75 and the 52-week low is $1.9. The market cap of the company stands at $29 M and there are 1,36,52,274 shares in public circulation.
Cancer Genetics Inc. is an oncology diagnostics company focused on developing commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors including cancer centers and hospitals biotechnology and biopharmaceutical companies and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological urogenital and HPV-associated cancers in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.